🔎 Trials Near Me

Dachaigh › Ailsean fala › Texas › Dallas

Sgrùdaidhean clionaigeach Ailsean fala ann an Dallas, TX

Tha 12 sgrùdaidhean airson Ailsean fala a’ lorg phàirtichean aig làraichean ann agus timcheall air Dallas (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.

Teacsa sgrùdaidh oifigeil (Beurla)

A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

A’ fastadhÌre 1
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT03816345

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

A’ fastadhÌre 2
  • UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT04728893

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

A’ fastadhÌre 3
  • Texas Oncology-Baylor Sammons Cancer Center ( Site 0062), Dallas
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT03486873

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

A’ fastadhÌre 1/2
  • Baylor Scott & White Health, Dallas
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT04588922

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

A’ fastadhÌre 3
  • Texas Oncology-Presbyterian Cancer Center, Dallas
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Lùna 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A’ fastadhÌre 1
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Lùna 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

A’ fastadhSgrùdadh amharc
  • Medical City Dallas, Dallas
  • Children's Medical Center Dallas, Dallas
Gach aois · Gach gnè · Air ùrachadh 6 Iuch 2026 · NCT01351545

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

A’ fastadhÌre 1
  • UT Southwestern Medical Center, Dallas
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Ògmh 2026 · NCT02074839

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

A’ fastadhÌre 3
  • Medical City Dallas Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Aoisean 2 gu 18 · Gach gnè · Air ùrachadh 5 Cèit 2026 · NCT05711667

Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant

A’ fastadh
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Aoisean 6 gu 29 · Gach gnè · Air ùrachadh 4 Cèit 2026 · NCT04678427

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

A’ fastadhÌre 1
  • UT Southwestern - Simmons Cancer Center, Dallas
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Màrt 2026 · NCT05735184

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

A’ fastadhÌre 1
  • University of Texas, Southwestern, Dallas
Aoisean 1 gu 21 · Gach gnè · Air ùrachadh 6 Dùbh 2024 · NCT05476770

Sgrùdaidhean Ailsean fala ann am bailtean eile

Sgrùdaidhean eile ann an Dallas

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.